Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study

Autores da FMUP
Participantes de fora da FMUP
- Estevinho, MM
Unidades de investigação
Abstract
LINKED CONTENT This article is linked to NOrgard et al paper. To view this article, visit
Dados da publicação
- ISSN/ISSNe:
- 0269-2813, 1365-2036
- Tipo:
- Editorial Material
- Páginas:
- 116-117
- DOI:
- 10.1111/apt.17543
- Link para outro recurso:
- www.scopus.com
ALIMENTARY PHARMACOLOGY & THERAPEUTICS Wiley-Blackwell Publishing Ltd
Citações Recebidas na Scopus: 1
Documentos
- Não há documentos
Filiações
Keywords
- AGE
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Estevinho MM,Magro F. Editorial: elderly onset inflammatory bowel disease --clues from the largest population--based cohort study. Aliment. Pharmacol. Ther. 2023. 58(1):p. 116-117. IF:7,600. (1).